Givens Daniel J, Karnell Lucy Hynds, Gupta Anjali K, Clamon Gerald H, Pagedar Nitin A, Chang Kristi E, Van Daele Douglas J, Funk Gerry F
Department of Otolaryngology-Head and Neck Surgery, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA.
Arch Otolaryngol Head Neck Surg. 2009 Dec;135(12):1209-17. doi: 10.1001/archoto.2009.174.
To assess toxicities, functional outcomes, and health-related quality of life associated with concurrent chemoradiation therapy (CRT) in patients with head and neck cancer.
Prospective and retrospective outcomes study.
Tertiary care institution.
Participants in the longitudinal Outcomes Assessment Project whose head and neck cancer was treated with CRT between February 1, 2000, and March 1, 2007 (n = 104).
Patients prospectively provided functional and health-related quality of life information, including data from the 1-year and most current follow-up visits. Medical records were reviewed to determine toxicity and survival rates.
Well-defined acute and late toxicities; functional outcomes (diet, dentition, tracheostomies); head and neck cancer-specific, general health, and depression outcomes; and survival rates.
Most patients had oropharyngeal or laryngeal tumors (87.5%) and advanced-stage disease (75.0%). Approximately one-half had hematologic toxicities and toxicity-related treatment delays. Approximately one-quarter had neurotoxicities and/or ototoxicites, moist desquamation, pneumonia, nausea and vomiting requiring hospitalization or intravenous fluids, dehydration or malnutrition requiring hospitalization, and mild or moderate fever. Although patients receiving the current intensity-modulated radiation therapy (IMRT) protocol using the Pinnacle(3) planning system had more toxicity-related treatment delays, they had fewer toxicities and better functional and health-related quality of life outcomes compared with those receiving conventional lateral opposing-field radiation or the initial IMRT protocol using the Best nomos PEACOCK planning system.
Patients receiving CRT experience a substantial number of treatment-related adverse events, primarily affecting oropharyngeal and laryngeal function, with improvement noted for the current IMRT protocol. Improving dental prosthetic rehabilitation and including evaluations with speech and swallowing pathologists before and during treatment may enhance patient outcomes.
评估头颈部癌患者同步放化疗(CRT)相关的毒性、功能结局及健康相关生活质量。
前瞻性和回顾性结局研究。
三级医疗机构。
参与纵向结局评估项目的患者,其头颈部癌于2000年2月1日至2007年3月1日期间接受CRT治疗(n = 104)。
患者前瞻性地提供功能及健康相关生活质量信息,包括来自1年及最近一次随访的数据。审查病历以确定毒性和生存率。
明确的急性和晚期毒性;功能结局(饮食、牙列、气管切开术);头颈部癌特异性、总体健康及抑郁结局;以及生存率。
大多数患者患有口咽或喉肿瘤(87.5%)且为晚期疾病(75.0%)。约一半患者有血液学毒性及与毒性相关的治疗延迟。约四分之一患者有神经毒性和/或耳毒性、湿性脱皮、肺炎、需住院或静脉补液的恶心和呕吐、需住院的脱水或营养不良以及轻或中度发热。尽管使用Pinnacle(3)计划系统接受当前调强放疗(IMRT)方案的患者有更多与毒性相关的治疗延迟,但与接受传统侧野对穿照射或使用Best nomos PEACOCK计划系统的初始IMRT方案的患者相比,他们毒性更少,功能及健康相关生活质量结局更好。
接受CRT的患者经历大量与治疗相关的不良事件,主要影响口咽和喉功能,当前IMRT方案有改善。改善假牙修复并在治疗前及治疗期间纳入言语和吞咽病理学家的评估可能会改善患者结局。